Alumis and ACELYRIN Join Forces to Drive Late-Stage Immunology Therapies

• Alumis Inc. and ACELYRIN, Inc. have entered into a definitive all-stock merger agreement.

• The combined entity expects to leverage a $737 million pro forma cash position to advance its immunology pipeline through key clinical milestones.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement under which both companies will combine in an all-stock transaction. The merger aims to enhance financial flexibility and support the advancement of a late-stage immunology pipeline.

With a pro forma cash position of approximately $737 million as of December 31, 2024, the newly merged company expects to fund operations, clinical trials, and capital expenditures into 2027. Alumis will integrate lonigutamab, a key asset from ACELYRIN, into its portfolio while continuing to develop ESK-001 for potential new indications.

Martin Babler, President, CEO, and Chairman of Alumis, stated, “Through this combination with ACELYRIN, Alumis will have the financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab, and build commercial capabilities.” He also emphasized upcoming development milestones expected in 2025 and 2026.

ACELYRIN’s Board of Directors conducted a strategic review before finalizing the deal. Bruce Cozadd, Chair of the ACELYRIN Board, commented, “This merger represents the culmination of a thorough strategic review process by our Board and management team to determine the best and most value-maximizing path forward for ACELYRIN.”

Looking ahead, the combined company plans to capitalize on shared development and commercial expertise, focusing on transformative medicines for immune-mediated diseases. With financial discipline and a flexible capital allocation strategy, the merged entity aims to maximize value for both patients and stockholders.